Aarti Drugs Limited announced a significant leadership transition with the retirement of Prakash M. Patil as Chairman, Managing Director, and Chief Executive Officer, effective September 30, 2026. Concurrently, Adhish P. Patil has been appointed as the new Managing Director, marking a generational shift in the company's top management.

Leadership changes effective October 1

The Board of Directors approved these changes at its meeting on July 31, 2026, which were subsequently ratified by shareholders at the 41st Annual General Meeting held on September 26, 2026. Prakash M. Patil resigned from his positions citing an intention to take early retirement, despite his current term being scheduled to expire on May 31, 2027. In his resignation letter, he stated that this timing allows for an orderly leadership transition.

Adhish P. Patil, who previously served as the Chief Financial Officer, has been promoted to the position of Managing Director with effect from October 1, 2026. Consequently, he relinquished the CFO role at the close of business hours on September 30, 2026. The company stated it will appoint a new Chief Financial Officer in due course to comply with Regulation 26A(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the transition

In his letter relinquishing the CFO post, Adhish P. Patil confirmed that he would continue to support and oversee functions under the purview of the CFO alongside his new responsibilities as Managing Director until a successor is appointed. This interim arrangement ensures continuity in financial oversight during the transition period.

The disclosures were made pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, read with Schedule III and the SEBI Circular dated January 30, 2026. The company emphasized that there were no material reasons for Prakash M. Patil's resignation other than his stated desire for early retirement.

Aarti Drugs Limited held its 41st Annual General Meeting on September 26, 2026, where shareholders approved several key appointments and adopted the audited financial statements for FY26. The meeting also featured an investor presentation highlighting strategic growth initiatives.

The meeting, conducted via Video Conferencing, saw 93 members participate. The agenda included the adoption of standalone and consolidated financial statements for the year ended March 31, 2026, alongside reports from the Board of Directors and Auditors. Shareholders also approved the "Aarti Drugs Limited Performance Stock Option Plan 2026" (PSOP 2026), which includes provisions for granting stock options to employees of subsidiary, group, and associate companies.

Leadership changes approved

Shareholders voted in favor of multiple resolutions concerning the company's board composition. The appointments mark a significant shift in the executive leadership structure.

Additionally, the re-appointment of three Independent Directors for a second term of five years was approved. These include Hasmukh Bhavanji Dedhia (99.91% For), Sandeep Madhusudan Joshi (99.95% For), and Ajit Eledath Venugopalan (99.91% For).

Financial performance highlights

The investor presentation disclosed consolidated financial results for FY26 and Q1FY27. For FY26, total revenue rose 7% YoY to ₹2,568 crore, while EBITDA increased to ₹312 crore with a margin of 12.1%. Profit after tax (PAT) grew 16% YoY to ₹195 crore, with PAT margin expanding to 7.6%.

Q1FY27 results showed stronger momentum, with revenue rising 19% YoY to ₹704 crore and EBITDA jumping 30% YoY to ₹97 crore. PBT increased 35% YoY to ₹69 crore.

Strategic growth and capacity expansion

The presentation outlined a strategic pivot toward scaling regulated market sales through the expansion of formulations and oncology product portfolios. The company has invested ₹200 crore over the last 24 months solely for oncology development. Key regulatory approvals received in FY26 include USFDA approval for the oncology facility and UK MHRA approval for the oral solid dosage (OSD) facility.

Capacity expansion remains a core focus. The Sayakha methylamines facility has been commissioned to strengthen backward integration for the Metformin portfolio. Installed capacity increased from 61,053 MT in FY25 to 82,512 MT in FY26. The company plans to scale anti-diabetic capacity from ~1,400 TPM to 2,000–2,200 TPM, with additional brownfield expansions underway.

What the numbers show

While FY26 revenue growth was modest at 7%, driven largely by volume gains of 7% offsetting a 3% price degrowth, Q1FY27 indicates a sharper recovery. The 19% revenue jump in Q1FY27 suggests that pricing stabilization is beginning to reflect in top-line performance. Furthermore, the shift in segment mix shows Speciality Chemicals growing to 11.7% of revenue in Q1FY27 from 7.0% in FY26, indicating successful diversification beyond traditional APIs.

A notable divergence emerged in the voting patterns for the PSOP 2026. While the resolution passed with 84.8% overall support due to unanimous promoter backing, public institutional investors voted overwhelmingly against it, with 99.7% casting votes in opposition. This contrasts sharply with the near-unanimous support (>99%) received for all director appointments and financial statement adoptions.

Other shareholder approvals

Other passed resolutions included payment of profit-related commission to non-executive directors (99.99% For), approval for Prakash Moreshwar Patil to hold an office or place of profit (97.85% For), and ratification of remuneration for cost auditors for FY27 (99.99% For). The meeting commenced at 11:00 am and concluded at 11:57 am. Remote e-voting facilities were available from September 23 to September 25, 2026.